Key vendors shift their focus from biologics to biosimilars
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five leading vendors for the global gastrointestinal therapeutics market in their latest research report. This report also lists 64 other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS). The report also considers the revenues expected to be generated from the sales of new drug launches in the market, along with the decline in revenues due to patent expiries of branded drugs during the forecast period.
This Technavio report, under the cardiovascular and metabolic disorders vertical, is based on the synthesis, analysis, and interpretation of information about the global gastrointestinal therapeutics market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The global market for gastrointestinal therapeutics is dominated by a few major players even though it is characterized by the presence of many large and small-scale vendors. Among the dominant players, Johnson & Johnson accounts for a major share of the gastrointestinal therapeutics market with its drugs like Remicade and Simponi. The market for these drugs is nearing maturity. However, the company is likely to retain its position as the market leader as the market for Simponi is expected to gain sales by 2020. AbbVie, another key player in the market, will also retain its market presence with drugs such as ABT-494, which is currently on trial for the treatment of Crohn’s disease. AbbVie is expected to pose as a tough competitor for Johnson & Johnson in the global gastrointestinal drugs market with its drug, Humira.
“The use of biologics for the treatment of inflammatory disorders is on the rise, spurred by an increase in the demand for quality care. However, this puts several countries in a tough spot as they have a limited healthcare budget. Biosimilars, unlike generic drugs, contain active pharmaceutical ingredients that are identical to their originator biologic compounds. Biosimilars are also less expensive than biologics, increasing accessibility and affordability. The patent expiry of biologics has led to the emergence of their biosimilars such as Inflectra (Remicade) and ABP 501 (HUMIRA),” says Abhay Sinha, a lead analyst at Technavio for research on lab equipment.
Top five vendors in the gastrointestinal therapeutics market space
AbbVie
AbbVie is a global biopharmaceutical company that engages in the development and marketing of advanced therapies for the treatment of diseases such as chronic autoimmune diseases, including psoriasis, rheumatoid arthritis, and Crohn’s disease; human immunodeficiency virus (HIV); hepatitis C; thyroid disease; endometriosis; and Parkinson’s disease. Wholesalers, independent retailers, specialty pharmacies, distributors, healthcare facilities, and government agencies constitute the company’s target audience. In FY2015, AbbVie reported revenue of almost $23 billion.
Key products: HUMIRA.
Johnson & Johnson
The company’s offerings include products for the infectious diseases, immunology, oncology, neuroscience, and metabolic and cardiovascular diseases therapy areas. Johnson & Johnson also develops and sells medical devices and consumer care products. It recorded revenue of more than $31 billion from the sales of pharmaceuticals in FY2015.
Key products: Remicade, and Simponi.
Takeda
Takeda is involved in the research, development, manufacture, sales, import, and export of pharmaceutical drugs. The company primary focus area is the development of drugs for gastroenterology, oncology, central nervous system diseases, and cardiovascular/metabolic disorders. The total revenue generated by the company’s drugs in Japan was almost $18 billion in FY2014.
Key products: Entyvio (ulcerative colitis and Crohn’s disease), Amitiza (IBS-C), Lansox (peptic ulcers), Dexilant (acid reflux disease), and Vonoprazan (acid-related diseases).
Allergan
Allergan, formerly known as Actavis, officially changed its name in February 2015. The company engages in the development of branded pharmaceuticals, biologics, and medical devices. Allergan’s key focus areas include the development of therapeutics for eye care, central nervous system, dermatology and medical aesthetics, women’s health, gastroenterology, anti-infectives, and urology drugs. The net revenue reported by the company in FY2015 was around $15 billion.
Key products: Asacol/Delzicol, Carafate/Sulcrate, Viberzi, and Linzess/Constella.
UCB
UCB Pharma’s primarily focus is the breakthrough treatment for severe diseases. The strategy of the company involves combining biology and chemistry through the use of projects such as A2HiT to develop drugs for therapeutic areas such as central nervous system and immunology. The total revenue generated by the company in FY2015 accounted to more than $4 billion.
Key products: Cimzia.
Other prominent vendors in this market include 4SC, Ajinomoto Pharmaceuticals, Alfa Wassermann, Alizyme, Amgen, Anterogen, Ardelyx, Arena Pharmaceuticals, Astellas, AstraZeneca, Astellas Pharma, Avaxia Biologics, Biogen Idec, BioLineRx, Celgene, ChemoCentryx, Drais Pharmaceuticals, Eisai, Eli Lilly, Enlivex Therapeutics, F. Hoffmann-La Roche, Ferring Pharmaceuticals, FF Pharma, Galapagos, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Kaken Pharmaceutical, Kang Stem Biotech, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lipid Therapeutics, Meda, Merck, Mesoblast, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Neovacs, Nestle, Norgine, Novartis, Ono Pharmaceutical, Pfizer, Procter & Gamble, Qu Biologics, Receptos, RedHill Biopharma, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Synergy Pharmaceuticals, Synthetic Biologics, TiGenix, Tillotts Pharma, TopiVert, TSD Japan, and Zeria Pharmaceutical.
A more detailed analysis is available in the Technavio report, ‘Global Gastrointestinal Therapeutics Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
To read more press releases- click here.
Browse related reports:
- Global Consumer Healthcare Market 2016-2020
- Global E-Coli Testing Market 2016-2020
- Global Gastrointestinal OTC Drugs Market 2015-2019
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
